Price History

Hover for the daily close. The dotted line marks the period open.

Compare CRBU with… →

CRBU Key Statistics

As of Sep 4, 2026

Trading

Open: $1.57
Previous Close: $1.57
Day's Range: 1.55–1.60
52-Week Range: 1.38–3.54
Volume: 1.32M
Beta: 2.28

Valuation

Market Cap: $168.32M
P/E Ratio: unprofitable
P/S ratio: 16.77
EPS (ttm): −1.08

Financials (FY)

Revenue (FY): $11.16M+11.66%
Net Income (FY): −$148.13M
Profit margin: 0.00%
Shares Outstanding: 107.21M
1-Year Return: −15.14%

Dividend and dates

Earnings Date: November 11, 2026estimated
Avg Volume: 1.70M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CRBU Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−7.54%−58.38%−8.76%−72.25%+0.00%−1.26%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−1.26%
2025	+0.00%
2024	−72.25%
2023	−8.76%
2022	−58.38%
2021 (partial year)	−7.54%

As of September 4, 2026.

CRBU Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$11.16M	−$148.13M	−1327.4%
2024	$9.99M	−$149.11M	−1491.9%
2023	$34.48M	−$102.07M	−296.1%
2022	$13.85M	−$99.42M	−717.8%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$11.16M	—	−$136.19M	−$148.13M	−1327.4%
2024	$9.99M	—	−$166.62M	−$149.11M	−1491.9%
2023	$34.48M	—	−$116.06M	−$102.07M	−296.1%
2022	$13.85M	—	−$106.40M	−$99.42M	−717.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CRBU Valuation vs Biotechnology Median

Median of 656 stocks

Metric	CRBU	Biotechnology median	vs median
P/S ratio	16.77	15.26	10% above
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Caribou Biosciences, Inc. (CRBU) at $168.32M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 97.

The 52-week range on file runs from $1.38 to $3.54. The most recent close on file for CRBU is $1.57, dated September 4, 2026. The close was unchanged from the previous session. The latest close sits 13.77% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $11.16M. That is +11.66% against the prior fiscal year, when revenue was $9.99M. The same year closed with a net loss of $148.13M. Profit margin runs at 0%. Trailing earnings per share are −1.08.

Across the 4 fiscal years on file, revenue moves from $13.85M in 2022 to $11.16M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 16.77 times revenue. On price-to-sales that is 9.89% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 2.28. Daily returns over the trailing 5 years annualize to a volatility of 84.4%. Over the trailing twelve months the price has returned −15.14%. Measured over 5 years, that is −44.56% a year compounded.

Growth & Income

No dividend is on file for CRBU.

2026 is still running; the price is −1.26% year to date. Across the complete calendar years on file, 2025 returned 0.00% and 2024 returned −72.25%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Caribou Biosciences, Inc. (CRBU) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Caribou Biosciences, Inc.	CRBU	$168.32M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Caribou Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Caribou Biosciences, Inc.

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Visit website →

Caribou Biosciences, Inc. (CRBU) Stock Analysis